Mays Cancer Center at UT Health San Antonio | Strategic Alliance Partners

February 25, 2020

Ruben Mesa, MD, discusses the adverse events of ruxolitinib and fedratinib in myelofibrosis.

January 28, 2020

Ruben A. Mesa, MD, discusses the approval of fedratinib in myelofibrosis and other JAK inhibitors in the treatment pipeline.

January 16, 2020

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the efficacy of fedratinib (Inrebic) in patients with myelofibrosis who have low platelet counts.

August 16, 2019

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the FDA approval of fedratinib (Inrebic) in myelofibrosis.

November 29, 2015

Although prolonged autophagy can result in cancer cell death, recent investigations suggest that therapy-induced autophagy is a reversible response that promotes cancer cell survival, and thus may diminish the efficacy of some therapeutic agents.

July 22, 2015

Even in seemingly uniform cell populations within subcompartments, cell-cell heterogeneity is becoming more evident, far beyond what was previously expected.

April 08, 2015

Andrew Brenner, MD, PhD, discusses how liposomal encapsulation of radiotherapeutics holds significant promise as a treatment of glioblastoma.

September 19, 2014

The Hispanic population in the United States represents the fastest-growing segment of the population (expected to reach 30% of the nation's total by 2050), and faces significant cancer health disparities

June 18, 2014

Although bacillus Calmette-Guérin (BCG) therapy has significantly improved outcomes for patients with non–muscle invasive bladder cancer since its introduction nearly 40 years ago, there is a pressing need to enhance responses to BCG and to distinguish which patients would respond to treatment early on in the course of therapy.

March 31, 2014

Ian M. Thompson, MD, director, professor, Department of Urology, Cancer Therapy & Research Center, The University of Texas Health Science Center, discusses the problems with prostate biopsies and some possible solutions.

March 24, 2014

Prodrug chemotherapy is an exciting approach by which higher concentrations of cytotoxic or biologically active agents can be achieved at a tumor site while avoiding the systemic toxicity of a non-cell-specific toxin.

September 25, 2013

World-class cancer research and treatment center is the latest to partner with OncLive to promote its research, events, and initiatives